vs
Side-by-side financial comparison of Protalix BioTherapeutics, Inc. (PLX) and TRANSCONTINENTAL REALTY INVESTORS INC (TCI). Click either name above to swap in a different company.
TRANSCONTINENTAL REALTY INVESTORS INC is the larger business by last-quarter revenue ($12.1M vs $9.1M, roughly 1.3× Protalix BioTherapeutics, Inc.). TRANSCONTINENTAL REALTY INVESTORS INC runs the higher net margin — 68.8% vs -60.3%, a 129.1% gap on every dollar of revenue. On growth, TRANSCONTINENTAL REALTY INVESTORS INC posted the faster year-over-year revenue change (2.3% vs -49.9%). Over the past eight quarters, TRANSCONTINENTAL REALTY INVESTORS INC's revenue compounded faster (0.7% CAGR vs -6.7%).
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
Transcontinental Realty Investors Inc. (TCI) is a U.S.-based real estate investment firm that owns, operates and develops a diversified portfolio of residential, commercial and mixed-use properties across core U.S. regional markets. It pursues long-term value growth via strategic property acquisitions, efficient asset management and tailored leasing solutions for individual and business tenants.
PLX vs TCI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.1M | $12.1M |
| Net Profit | $-5.5M | $8.3M |
| Gross Margin | 49.4% | — |
| Operating Margin | -51.1% | -28.9% |
| Net Margin | -60.3% | 68.8% |
| Revenue YoY | -49.9% | 2.3% |
| Net Profit YoY | -184.8% | 7577.8% |
| EPS (diluted) | $-0.06 | $0.97 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.1M | $12.1M | ||
| Q3 25 | $17.9M | $12.8M | ||
| Q2 25 | $15.7M | $12.2M | ||
| Q1 25 | $10.1M | $12.0M | ||
| Q4 24 | $18.2M | $11.8M | ||
| Q3 24 | $18.0M | $11.6M | ||
| Q2 24 | $13.5M | $11.8M | ||
| Q1 24 | — | $11.9M |
| Q4 25 | $-5.5M | $8.3M | ||
| Q3 25 | $2.4M | $724.0K | ||
| Q2 25 | $164.0K | $169.0K | ||
| Q1 25 | $-3.6M | $4.6M | ||
| Q4 24 | $6.5M | $108.0K | ||
| Q3 24 | $3.2M | $1.7M | ||
| Q2 24 | $-2.2M | $1.5M | ||
| Q1 24 | — | $2.5M |
| Q4 25 | 49.4% | — | ||
| Q3 25 | 53.4% | — | ||
| Q2 25 | 62.5% | — | ||
| Q1 25 | 19.1% | — | ||
| Q4 24 | 78.7% | — | ||
| Q3 24 | 53.4% | — | ||
| Q2 24 | 29.8% | — | ||
| Q1 24 | — | — |
| Q4 25 | -51.1% | -28.9% | ||
| Q3 25 | 11.9% | -10.9% | ||
| Q2 25 | 7.5% | -6.8% | ||
| Q1 25 | -41.0% | -5.3% | ||
| Q4 24 | 39.6% | -14.3% | ||
| Q3 24 | 22.2% | -14.4% | ||
| Q2 24 | -18.0% | -9.2% | ||
| Q1 24 | — | -11.2% |
| Q4 25 | -60.3% | 68.8% | ||
| Q3 25 | 13.2% | 5.6% | ||
| Q2 25 | 1.0% | 1.4% | ||
| Q1 25 | -35.8% | 38.5% | ||
| Q4 24 | 35.6% | 0.9% | ||
| Q3 24 | 18.0% | 14.7% | ||
| Q2 24 | -16.4% | 12.7% | ||
| Q1 24 | — | 21.4% |
| Q4 25 | $-0.06 | $0.97 | ||
| Q3 25 | $0.03 | $0.08 | ||
| Q2 25 | $0.00 | $0.02 | ||
| Q1 25 | $-0.05 | $0.53 | ||
| Q4 24 | $0.10 | $0.01 | ||
| Q3 24 | $0.03 | $0.20 | ||
| Q2 24 | $-0.03 | $0.17 | ||
| Q1 24 | — | $0.30 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $14.7M | $89.0M |
| Total DebtLower is stronger | — | $210.8M |
| Stockholders' EquityBook value | $48.2M | $846.7M |
| Total Assets | $82.3M | $1.1B |
| Debt / EquityLower = less leverage | — | 0.25× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $14.7M | $89.0M | ||
| Q3 25 | $13.6M | $82.7M | ||
| Q2 25 | $17.9M | $73.5M | ||
| Q1 25 | $19.5M | $88.6M | ||
| Q4 24 | $19.8M | $99.7M | ||
| Q3 24 | $27.4M | $131.6M | ||
| Q2 24 | $23.4M | $127.5M | ||
| Q1 24 | — | $130.8M |
| Q4 25 | — | $210.8M | ||
| Q3 25 | — | $223.5M | ||
| Q2 25 | — | $212.4M | ||
| Q1 25 | — | $198.2M | ||
| Q4 24 | — | $181.9M | ||
| Q3 24 | — | $180.3M | ||
| Q2 24 | — | $177.4M | ||
| Q1 24 | — | $178.3M |
| Q4 25 | $48.2M | $846.7M | ||
| Q3 25 | $52.9M | $838.4M | ||
| Q2 25 | $49.9M | $837.7M | ||
| Q1 25 | $45.2M | $837.3M | ||
| Q4 24 | $43.2M | $832.3M | ||
| Q3 24 | $32.4M | $832.2M | ||
| Q2 24 | $28.6M | $830.4M | ||
| Q1 24 | — | $828.9M |
| Q4 25 | $82.3M | $1.1B | ||
| Q3 25 | $82.3M | $1.1B | ||
| Q2 25 | $78.5M | $1.1B | ||
| Q1 25 | $73.9M | $1.1B | ||
| Q4 24 | $73.4M | $1.1B | ||
| Q3 24 | $61.6M | $1.1B | ||
| Q2 24 | $91.5M | $1.0B | ||
| Q1 24 | — | $1.0B |
| Q4 25 | — | 0.25× | ||
| Q3 25 | — | 0.27× | ||
| Q2 25 | — | 0.25× | ||
| Q1 25 | — | 0.24× | ||
| Q4 24 | — | 0.22× | ||
| Q3 24 | — | 0.22× | ||
| Q2 24 | — | 0.21× | ||
| Q1 24 | — | 0.22× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.0M | $-2.9M |
| Free Cash FlowOCF − Capex | $1.6M | — |
| FCF MarginFCF / Revenue | 17.8% | — |
| Capex IntensityCapex / Revenue | 4.4% | — |
| Cash ConversionOCF / Net Profit | — | -0.35× |
| TTM Free Cash FlowTrailing 4 quarters | $-13.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.0M | $-2.9M | ||
| Q3 25 | $-3.7M | $8.2M | ||
| Q2 25 | $-5.2M | $-2.9M | ||
| Q1 25 | $-5.1M | $-7.4M | ||
| Q4 24 | $4.0M | $1.3M | ||
| Q3 24 | $4.1M | $13.7M | ||
| Q2 24 | $-3.6M | $-511.0K | ||
| Q1 24 | — | $3.9M |
| Q4 25 | $1.6M | — | ||
| Q3 25 | $-4.2M | — | ||
| Q2 25 | $-5.7M | — | ||
| Q1 25 | $-5.4M | — | ||
| Q4 24 | $3.6M | — | ||
| Q3 24 | $4.0M | — | ||
| Q2 24 | $-3.8M | — | ||
| Q1 24 | — | — |
| Q4 25 | 17.8% | — | ||
| Q3 25 | -23.7% | — | ||
| Q2 25 | -36.2% | — | ||
| Q1 25 | -53.0% | — | ||
| Q4 24 | 19.6% | — | ||
| Q3 24 | 22.4% | — | ||
| Q2 24 | -28.1% | — | ||
| Q1 24 | — | — |
| Q4 25 | 4.4% | — | ||
| Q3 25 | 2.8% | — | ||
| Q2 25 | 2.8% | — | ||
| Q1 25 | 3.0% | — | ||
| Q4 24 | 2.3% | — | ||
| Q3 24 | 0.5% | — | ||
| Q2 24 | 1.3% | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -0.35× | ||
| Q3 25 | -1.58× | 11.28× | ||
| Q2 25 | -31.91× | -17.24× | ||
| Q1 25 | — | -1.61× | ||
| Q4 24 | 0.61× | 12.13× | ||
| Q3 24 | 1.27× | 8.03× | ||
| Q2 24 | — | -0.34× | ||
| Q1 24 | — | 1.52× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
TCI
Segment breakdown not available.
